• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Biomimetic Nanovaccines: a Novel Approach in Immunization
Curr Pharm Des. 2023 May 29. doi: 10.2174/1381612829666230529094128. Online ahead of print.ABSTRACTAs the World Health Organization (WHO) declared, vaccines prevent an average of 2-3 million deaths yearly from diseases. However, effective prophylactic and therapeutic vaccines have yet to be developed for eradicating the deadliest diseases, viz., types of cancer, malaria, human immunodeficiency virus (HIV), and most serious microbial infections. Furthermore, scores of the existing vaccines have disadvantages, such as failure to completely stimulate the immune system, in vivo instability, high toxicity, need for the cold cha...
Source: Current Pharmaceutical Design - May 31, 2023 Category: Drugs & Pharmacology Authors: Javad Yaghmoorian Khojini Benjamin Babaei Maryam Shakarami Mahdis Mofidi Zahra Tahershamsi Tahura Fayeghi Arjmand Amir Tajbakhsh Seyed Mohammad Gheibihayat Source Type: research

In vitro antiviral activity of piperidine alkaloids from Senna spectabilis flowers on Chikungunya virus infection
CONCLUSION: The data presented herein show that compounds 1 and 2 have potential for being repurposed as anti-CHIKV drug. Our promising in vitro results encourage further in vitro and in vivo assays. This is the first description of the antiviral activity of compounds 1 and 2 against CHIKV infection, which can impact the development of antiviral drug candidates against chikungunya fever, which sometimes can be debilitating.PMID:35882766 | DOI:10.1007/s43440-022-00381-0
Source: Pharmacological Reports - July 26, 2022 Category: Drugs & Pharmacology Authors: Thamires Rodrigues Freitas Raul Marques Novais Igor Andrade Santos Daniel Oliveira Silva Martins Amanda Danuello Vanderlan da Silva Bolzani Ana Carolina Gomes Jardim Marcos Pivatto Source Type: research

Nucleic Acid-based Immuno-prophylaxis and -therapies against Tropical Diseases
Yakugaku Zasshi. 2022;142(7):709-713. doi: 10.1248/yakushi.21-00210-5.ABSTRACTThe number of clinical trials investigating the use of nucleic acid drugs, including DNA/RNA-based vaccines, immunostimulatory/modulatory DNA/RNA and cyclic dinucleotides, for immuno-prophylaxis and -therapy has been increasing exponentially in recent years. These new drugs have revealed their therapeutic potential not only as vaccines or adjuvant therapies, but also as monotherapies for use in immuno-therapy of cancer and allergic disease. I will present an overview of their current R&D taking place in this field, then describe our recent pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 5, 2022 Category: Drugs & Pharmacology Authors: Ken J Ishii Source Type: research

Corporate Efforts to Research and Develop Therapeutic Agents for Infectious Diseases That Threaten Human
Yakugaku Zasshi. 2022;142(7):691-696. doi: 10.1248/yakushi.21-00210-2.ABSTRACTOvercoming serious infectious diseases such as malaria, tuberculosis, and other neglected tropical diseases (NTDs) that threaten human life around the world is an important issue in global health. Most of these diseases are concentrated in developing and low-income countries, and in order to reinforce drug discovery activities, pharmaceutical companies are actively promoting industry-academia-government partnerships and utilizing funds to stimulate global health activities. In this presentation, three examples of our drug discovery activities are...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 5, 2022 Category: Drugs & Pharmacology Authors: Ryu Yoshida Rina Kaki Osamu Yoshida Takao Shishido Teruhisa Kato Yoshinori Yamano Source Type: research

Nucleic Acid-based Immuno-prophylaxis and -therapies against Tropical Diseases
Yakugaku Zasshi. 2022;142(7):709-713. doi: 10.1248/yakushi.21-00210-5.ABSTRACTThe number of clinical trials investigating the use of nucleic acid drugs, including DNA/RNA-based vaccines, immunostimulatory/modulatory DNA/RNA and cyclic dinucleotides, for immuno-prophylaxis and -therapy has been increasing exponentially in recent years. These new drugs have revealed their therapeutic potential not only as vaccines or adjuvant therapies, but also as monotherapies for use in immuno-therapy of cancer and allergic disease. I will present an overview of their current R&D taking place in this field, then describe our recent pr...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 5, 2022 Category: Drugs & Pharmacology Authors: Ken J Ishii Source Type: research

Corporate Efforts to Research and Develop Therapeutic Agents for Infectious Diseases That Threaten Human
Yakugaku Zasshi. 2022;142(7):691-696. doi: 10.1248/yakushi.21-00210-2.ABSTRACTOvercoming serious infectious diseases such as malaria, tuberculosis, and other neglected tropical diseases (NTDs) that threaten human life around the world is an important issue in global health. Most of these diseases are concentrated in developing and low-income countries, and in order to reinforce drug discovery activities, pharmaceutical companies are actively promoting industry-academia-government partnerships and utilizing funds to stimulate global health activities. In this presentation, three examples of our drug discovery activities are...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 5, 2022 Category: Drugs & Pharmacology Authors: Ryu Yoshida Rina Kaki Osamu Yoshida Takao Shishido Teruhisa Kato Yoshinori Yamano Source Type: research

Studies on Activities and Chemical Characterization of Medicinal Plants in Search for New Antimalarials: A Ten Year Review on Ethnopharmacology
Malaria is an endemic disease that affected 229 million people and caused 409 thousand deaths, in 2019. Disease control is based on early diagnosis and specific treatment with antimalarial drugs since no effective vaccines are commercially available to prevent the disease. Drug chemotherapy has a strong historical link to the use of traditional plant infusions and other natural products in various cultures. The research based on such knowledge has yielded two drugs in medicine: the alkaloid quinine from Cinchona species, native in the Amazon highland rain forest in South America, and artemisinin from Artemisia annua, a spe...
Source: Frontiers in Pharmacology - September 22, 2021 Category: Drugs & Pharmacology Source Type: research

Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis - A review
Biomed Pharmacother. 2021 Jul 20;141:111920. doi: 10.1016/j.biopha.2021.111920. Online ahead of print.ABSTRACTThe study of tropical diseases like leishmaniasis, a parasitic disease, has not received much attention even though it is the second-largest infectious disease after malaria. As per the WHO report, a total of 0.7-1.0 million new leishmaniasis cases, which are spread by 23 Leishmania species in more than 98 countries, are estimated with an alarming 26,000-65,000 death toll every year. Lack of potential vaccines along with the cost and toxicity of amphotericin B (AmB), the most common drug for the treatment of leishm...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 30, 2021 Category: Drugs & Pharmacology Authors: Pragya Prasanna Prakash Kumar Saurabh Kumar Vinod Kumar Rajana Vishnu Kant Surendra Rajit Prasad Utpal Mohan V Ravichandiran Debabrata Mandal Source Type: research

Development of Medicines for Infectious Diseases -Malaria.
Abstract In developed countries, it is said that "threats of infectious diseases are already thought as things of the past". However, as you can see in the case of Ebola hemorrhagic fever that occurred in West Africa, this is a big mistake. Among infectious diseases, only smallpox has been successfully eradicated worldwide. In addition to the three major infectious diseases of HIV/AIDS, tuberculosis, and malaria, there is another group called emerging and reemerging infectious diseases. Recently, neglected tropical diseases (NTDs) have been listed as threats by the WHO, as have drug-resistant bacteria. The spread ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - July 3, 2020 Category: Drugs & Pharmacology Authors: Kita K Tags: Yakugaku Zasshi Source Type: research

Current Drugs with Potential for Treatment of COVID-19: A Literature Review.
CONCLUSION: All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use. PMID: 32251618 [PubMed - as supplied by publisher]
Source: J Pharm Pharm Sci - April 7, 2020 Category: Drugs & Pharmacology Authors: Md Insiat Islam Rabby Tags: J Pharm Pharm Sci Source Type: research

Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review
ConclusionThe most advanced phase III clinical applications led to the development of two vaccines containing QS-21 as part of AS, the Herpes Zoster vaccine (HZ/su) (ShingrixTM) which received a license in 2017 from the FDA and a marketing authorization in EU in 2018 and the RTS,S/AS01 vaccine (MosquirixTM) against malaria which was approved by the EMA in 2015 for further implementation in Sub Saharan countries for routine use.Graphical abstract
Source: Phytomedicine - April 1, 2019 Category: Drugs & Pharmacology Source Type: research